NextCure (NASDAQ:NXTC) Stock Rating Lowered by Wall Street Zen

NextCure (NASDAQ:NXTC – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

NXTC has been the subject of several other research reports. Weiss Ratings raised NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 10th. HC Wainwright reaffirmed a “buy” rating on shares of NextCure in a report on Thursday, August 13th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $20.00.

Read Our Latest Report on NXTC

NextCure Price Performance

NASDAQ NXTC opened at $6.40 on Friday. NextCure has a 1 year low of $1.55 and a 1 year high of $15.74. The company has a market capitalization of $29.31 million, a PE ratio of -0.95 and a beta of 1.22. The company has a fifty day moving average of $5.98 and a 200 day moving average of $7.55.

NextCure (NASDAQ:NXTC – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.39).

Insider Buying and Selling at NextCure

In related news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock in a transaction that occurred on Friday, October 23rd. The stock was purchased at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the transaction, the insider directly owned 728,045 shares in the company, valued at approximately $3,516,457.35. This trade represents a 0.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders have bought 15,537 shares of company stock worth $77,603. 11.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NextCure

An institutional investor recently raised its stake in NextCure stock. Renaissance Technologies LLC raised its holdings in shares of NextCure, Inc. (NASDAQ:NXTC – Free Report) by 80.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,534 shares of the company’s stock after buying an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 42.65% of the company’s stock.

About NextCure

(Get Free Report)

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products. Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates.

Further Reading

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.